Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | DRD4 | P21917 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075644 | 0.88 | AR (0.65) | DRD2DRD4DRD3ARKCNH2 | |
| SCHEMBL3080354 | 0.86 | AR (0.61) | DRD2DRD4DRD3ARKCNH2 | |
| SCHEMBL5197067 | 0.72 | DRD2 (1.00) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL7504732 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL12084221 | 0.71 | AR (0.81) | DRD2DRD4DRD3ARKCNH2 | |
| SCHEMBL7504561 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3KCNH2HTR1A | |
| SCHEMBL3077396 | 0.71 | AR (1.00) | DRD2DRD4DRD3ARKCNH2 | |
| SCHEMBL3066696 | 0.70 | AR (0.68) | ARKCNH2 | |
| SCHEMBL3079193 | 0.69 | AR (0.70) | ARKCNH2 | |
| SCHEMBL3068661 | 0.69 | AR (0.77) | DRD2DRD4DRD3ARKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | claimed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | claimed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | claimed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | DRD2 2254/4885DRD4 2466/4885DRD3 855/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | DRD2 2373/4885DRD4 2484/4885DRD3 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.